文献速递新生儿儿童呼吸

澳大利亚两家三级新生儿病房引入微创肺表面活性物质治疗后的结局

Outcomes after Introduction of Minimally Invasive Surfactant Therapy in Two Australian Tertiary Neonatal Units.
PubMed 文献 · J Pediatr · 2020-10-14

该前瞻性审计在2018年MIST引入后18个月内记录两家澳大利亚三级新生儿重症监护病房的135例MIST操作(122名婴儿)。操作中血氧饱和度降至80%以下常见(75.2%),阿托品预给药与心动过缓发生率显著降低相关(8.6% vs 52.9%,P < .01),多数婴儿(63.9%)后续无需气管插管和机械通气。

要点

  • MIST可在该技术经验有限的新生儿病房成功开展。
  • 阿托品预给药可降低操作期间心动过缓发生率。
  • 由气管插管更熟练的临床医生操作可优化成功率。

核心结论

  • MIST可在对该技术经验有限的新生儿病房成功引入。
  • 阿托品预给药可降低MIST操作期间心动过缓的发生率。
  • 将MIST限制由气管插管能力更强的临床医生操作可优化成功率。

研究设计与样本

  • 研究为在2018年MIST引入前设计的前瞻性审计,数据收集持续18个月。
  • 共记录122名婴儿的135例MIST操作。
  • 纳入婴儿中位胎龄302/7周(IQR,276/7至322/7周),出生体重1439 g(IQR,982-1958 g)。

主要发现

  • MIST操作期间外周血氧饱和度降至<80%常见,发生于75.2%的操作。
  • 其他不良事件包括需要正压通气(10.6%)和心率<100次/分的心动过缓(13.3%)。
  • 阿托品预给药与心动过缓发生率显著降低相关:8.6% vs 52.9%(P < .01)。
  • 高级临床医生的操作成功率更高。
  • 接受MIST治疗的婴儿中多数(63.9%)后续无需气管插管和机械通气。

临床怎么用

  • 在经验有限的新生儿病房引入MIST时,可考虑阿托品预给药以降低操作期间心动过缓风险。
  • 可由气管插管能力更强的临床医生实施MIST以优化成功率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the procedural and clinical outcomes associated with the introduction of minimally invasive surfactant therapy (MIST) into standard care at 2 tertiary Australian neonatal intensive care units. STUDY DESIGN: A prospective audit was designed before the introduction of MIST in 2018, with data collected over a period of 18 months. Procedural data were completed by the clinical team performing MIST, including clinical observations, medication use, and adverse events. The audit team collected demographic data and subsequent clinical outcomes from medical records. RESULTS: There were 135 MIST procedures recorded in 122 infants. For the included infants, the median gestation was 302/7 weeks (IQR, 276/7 to 322/7 weeks) and birth weight was 1439 g (IQR, 982-1958 g). During the MIST procedure, desaturation to a peripheral oxygen saturation of <80% was common, occurring in 75.2% of procedures. Other adverse events included need for positive pressure ventilation (10.6%) and bradycardia <100 beats per minute (13.3%). The use of atropine premedication was associated with a significantly lower incidence of bradycardia: 8.6% vs 52.9% (P < .01). Senior clinicians demonstrated higher rates of procedural success. The majority of infants (63.9%) treated with MIST did not require subsequent intubation and mechanical ventilation. CONCLUSIONS: MIST can be successfully introduced in neonatal units with limited experience of this technique. The use of atropine premedication decreases the incidence of bradycardia during the procedure. Success rates can be optimized by limiting MIST to clinicians with greater competence in endotracheal intubation.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Roberts CT, Halibullah I, Bhatia R, et al. Outcomes after Introduction of Minimally Invasive Surfactant Therapy in Two Australian Tertiary Neonatal Units. J Pediatr. 2020. PMID: 33068569. doi:10.1016/j.jpeds.2020.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。